For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a lower risk for venous thromboembolism (VTE).
There was an increase in dyslipidemia incidence during the COVID-19 pandemic compared with the prepandemic period.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback